Advanced search
Publication Cover
Biotechnology & Biotechnological Equipment Volume 37, 2023 - Issue 1
Submit an article Journal homepage
1,150
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Conducting clinical trials in five Eastern European countries (EU-EECs) with a focus on Bulgaria

Tatyana Benishevaa Department of Health Policy and Management, Faculty of Public Health, Medical University of Sofia, BulgariaCorrespondence[email protected]
View further author information
,
Dimitar Milkova Department of Health Policy and Management, Faculty of Public Health, Medical University of Sofia, BulgariaView further author information
,
Valentin Kopanarova Department of Health Policy and Management, Faculty of Public Health, Medical University of Sofia, BulgariaView further author information
,
Ivaylo Ivanovb Pharmaceutical Research Associates Bulgaria EOOD, Sofia, BulgariaView further author information
,
Dimitar Dimitrova Department of Health Policy and Management, Faculty of Public Health, Medical University of Sofia, BulgariaView further author information
,
Veselina Todorovaa Department of Health Policy and Management, Faculty of Public Health, Medical University of Sofia, BulgariaView further author information
,
Nigyar Dzhafera Department of Health Policy and Management, Faculty of Public Health, Medical University of Sofia, BulgariaView further author information
,
Iva Chavkovaa Department of Health Policy and Management, Faculty of Public Health, Medical University of Sofia, BulgariaView further author information
,
Lyubina Todorovac Department of Marketing Authorisation of Medicinal Products, Bulgarian Drug Agency, Sofia, BulgariaView further author information
&
Lena Gebertd Global Regulatory Oncology Division, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
 show all
Article: 2226741 | Received 03 Apr 2023, Accepted 13 Jun 2023, Published online: 02 Jul 2023

Figures & data

Figure 1. Clinical trials in Bulgaria 1995–2021 (source BDA reports) [Citation5].

Figure 1. Clinical trials in Bulgaria 1995–2021 (source BDA reports) [Citation5].

Figure 2. Cumulative number of completed and ongoing clinical trials from 1 January 2012 to 30 September 2022 (Phases I, II, III) [Citation4].

Figure 2. Cumulative number of completed and ongoing clinical trials from 1 January 2012 to 30 September 2022 (Phases I, II, III) [Citation4].

Figure 3. Number of clinical trials per 100,000 inhabitants, completed and ongoing for the period of 1 January 2012 until 30 September 2022 (Phases I, II, III) [Citation4, Citation22].

Figure 3. Number of clinical trials per 100,000 inhabitants, completed and ongoing for the period of 1 January 2012 until 30 September 2022 (Phases I, II, III) [Citation4, Citation22].

Figure 4. Distribution of completed and ongoing clinical trials for the period from 1 January 2012 until 30 September 2022 (Phases I, II, III) [Citation4].

Figure 4. Distribution of completed and ongoing clinical trials for the period from 1 January 2012 until 30 September 2022 (Phases I, II, III) [Citation4].

Figure 5. Distribution of Phases I, II and III of completed and ongoing clinical trials in the five EU-EECs for the period from 1 January 2012 until 30 September 2022 (presented as %) [Citation4].

Figure 5. Distribution of Phases I, II and III of completed and ongoing clinical trials in the five EU-EECs for the period from 1 January 2012 until 30 September 2022 (presented as %) [Citation4].

Figure 6. Distribution of completed and ongoing clinical trials (Phases I, II and III) in the five EU-EECs from 1 January 2012 to 30 September 2022, of rare disease indications and in pediatric patients [Citation4].

Figure 6. Distribution of completed and ongoing clinical trials (Phases I, II and III) in the five EU-EECs from 1 January 2012 to 30 September 2022, of rare disease indications and in pediatric patients [Citation4].

Figure 7. Total number of completed and ongoing clinical trials (Phases I, II and III) with rare disease indications and with pediatric patients from 1 January 2012 until 30 September 2022 [Citation4].

Figure 7. Total number of completed and ongoing clinical trials (Phases I, II and III) with rare disease indications and with pediatric patients from 1 January 2012 until 30 September 2022 [Citation4].

Figure 8. Total number of completed and ongoing clinical trials (Phases I, II and III) in all EU Member States from 1 January 2012 until 30 September 2022 [Citation4].

Figure 8. Total number of completed and ongoing clinical trials (Phases I, II and III) in all EU Member States from 1 January 2012 until 30 September 2022 [Citation4].

Figure 9. Completed and ongoing clinical trials (Phases I, II and III) per 100,000 inhabitants in all EU Member States [Citation4].

Figure 9. Completed and ongoing clinical trials (Phases I, II and III) per 100,000 inhabitants in all EU Member States [Citation4].

Data availability statement

Data are based on the EU Clinical Trials Register, which is open and data extraction is given under every figure and is under Reference [Citation4] EU Clinical Trials Register, https://www.clinicaltrialsregister.eu

EUROSTAT. GDP per capita in PPS, https://ec.europa.eu/eurostat/databrowser/view/tec00114/default/table?lang=en

EUROSTAT. Total population of the European Union, https://ec.europa.eu/eurostat/cache/digpub/demography/vis/00_00_00/index.html?lang=en

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.